Danaher (NYSE:DHR - Get Free Report) is scheduled to be posting its quarterly earnings results before the market opens on Tuesday, April 23rd. Analysts expect the company to announce earnings of $1.74 per share for the quarter. Individual interested in listening to the company's earnings conference call can do so using this link.
Danaher (NYSE:DHR - Get Free Report) last released its earnings results on Tuesday, January 30th. The conglomerate reported $2.09 EPS for the quarter, beating analysts' consensus estimates of $1.91 by $0.18. The firm had revenue of $6.41 billion for the quarter, compared to analysts' expectations of $6.10 billion. Danaher had a return on equity of 12.25% and a net margin of 17.26%. The company's quarterly revenue was down 10.2% on a year-over-year basis. During the same quarter in the prior year, the firm posted $2.87 earnings per share. On average, analysts expect Danaher to post $8 EPS for the current fiscal year and $9 EPS for the next fiscal year.
Danaher Stock Up 0.3 %
Shares of Danaher stock traded up $0.69 during trading on Tuesday, hitting $240.35. 3,225,223 shares of the stock traded hands, compared to its average volume of 2,703,507. Danaher has a 52-week low of $182.09 and a 52-week high of $259.00. The stock's fifty day simple moving average is $249.58 and its 200 day simple moving average is $229.84. The firm has a market cap of $177.99 billion, a P/E ratio of 37.51, a price-to-earnings-growth ratio of 3.65 and a beta of 0.83. The company has a current ratio of 1.68, a quick ratio of 1.37 and a debt-to-equity ratio of 0.31.
Danaher Increases Dividend
The business also recently announced a quarterly dividend, which will be paid on Friday, April 26th. Shareholders of record on Thursday, March 28th will be issued a dividend of $0.27 per share. The ex-dividend date is Wednesday, March 27th. This represents a $1.08 dividend on an annualized basis and a yield of 0.45%. This is a positive change from Danaher's previous quarterly dividend of $0.24. Danaher's dividend payout ratio is currently 16.90%.
Insider Buying and Selling
In other news, SVP Daniel Raskas sold 23,757 shares of the firm's stock in a transaction dated Monday, February 26th. The stock was sold at an average price of $252.00, for a total transaction of $5,986,764.00. Following the sale, the senior vice president now directly owns 38,102 shares in the company, valued at approximately $9,601,704. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In other Danaher news, Director Walter G. Lohr sold 3,289 shares of the company's stock in a transaction on Thursday, February 15th. The shares were sold at an average price of $251.15, for a total transaction of $826,032.35. Following the completion of the transaction, the director now directly owns 14,129 shares in the company, valued at $3,548,498.35. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Daniel Raskas sold 23,757 shares of Danaher stock in a transaction dated Monday, February 26th. The shares were sold at an average price of $252.00, for a total transaction of $5,986,764.00. Following the completion of the sale, the senior vice president now owns 38,102 shares in the company, valued at approximately $9,601,704. The disclosure for this sale can be found here. Over the last three months, insiders have sold 32,957 shares of company stock valued at $8,265,802. Corporate insiders own 10.90% of the company's stock.
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently bought and sold shares of the stock. Hobbs Group Advisors LLC purchased a new stake in shares of Danaher during the fourth quarter worth approximately $43,000. Sanibel Captiva Trust Company Inc. acquired a new stake in shares of Danaher in the fourth quarter valued at about $4,194,000. Oarsman Capital Inc. lifted its stake in shares of Danaher by 54.0% in the fourth quarter. Oarsman Capital Inc. now owns 1,466 shares of the conglomerate's stock worth $339,000 after buying an additional 514 shares in the last quarter. Harbour Investments Inc. boosted its position in Danaher by 14.8% during the fourth quarter. Harbour Investments Inc. now owns 1,429 shares of the conglomerate's stock worth $331,000 after acquiring an additional 184 shares during the last quarter. Finally, O Dell Group LLC purchased a new stake in Danaher during the 4th quarter valued at about $64,000. 79.05% of the stock is owned by hedge funds and other institutional investors.
Analyst Ratings Changes
A number of research firms recently commented on DHR. HSBC started coverage on shares of Danaher in a research report on Monday, December 18th. They set a "hold" rating for the company. Royal Bank of Canada raised their target price on Danaher from $254.00 to $282.00 and gave the stock an "outperform" rating in a research note on Wednesday, January 31st. JPMorgan Chase & Co. boosted their price target on Danaher from $250.00 to $270.00 and gave the company an "overweight" rating in a research note on Wednesday, December 20th. Citigroup raised their price objective on Danaher from $255.00 to $280.00 and gave the stock a "buy" rating in a research note on Wednesday, January 31st. Finally, Raymond James increased their price target on shares of Danaher from $240.00 to $270.00 and gave the stock an "outperform" rating in a report on Wednesday, January 31st. Seven investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company's stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $267.43.
Read Our Latest Stock Analysis on Danaher
Danaher Company Profile
(
Get Free Report)
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.
See Also
Before you consider Danaher, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Danaher wasn't on the list.
While Danaher currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
